Open AccessBone Marrow Findings in Patients With Acute Promyelocytic Leukemia Treated With Arsenic Trioxide
Author(s) -
Kurt W. Miller,
Girish Venkataraman,
Christopher D. Gocke,
Denise Batista,
Michael J. Borowitz,
Kathleen H. Burns,
Keith W. Pratz,
Amy S. Duffield
Publication year - 2019
Publication title -
american journal of clinical pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.859
H-Index - 128
eISSN - 1943-7722
pISSN - 0002-9173
DOI - 10.1093/ajcp/aqz087
Subject(s) - arsenic trioxide , acute promyelocytic leukemia , bone marrow , medicine , tretinoin , myeloid , atypia , leukemia , pathology , biopsy , myeloid leukemia , cancer research , retinoic acid , chemistry , arsenic , biochemistry , organic chemistry , gene
Increasingly, acute promyelocytic leukemia (APL) is treated with a combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). This study characterizes bone marrow findings after ATRA/ATO therapy.